4H-Pyrido[1,2-a]pyrimidin-4-one, 9-methyl-3-(2H-tetrazol-5-yl)-, potassium salt (1:1)
| Title | Journal |
|---|---|
| Pemirolast reduces cisplatin-induced kaolin intake in rats. | European journal of pharmacology 20110701 |
| [Toxicity of topical ocular anti-allergic agents on human corneal epithelial cells in vitro]. | [Zhonghua yan ke za zhi] Chinese journal of ophthalmology 20100101 |
| Suppressive activity of pemirolast potassium, an antiallergic drug, on glomerulonephritis. Studies in glomerulonephritis model rats and in patients with chronic glomerulonephritis concurrently affected by allergic rhinitis. | Arzneimittel-Forschung 20080101 |
| The effect of a combined therapy with a histamine H1 antagonist and a chemical mediator release inhibitor on allergic conjunctivitis. | Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde 20080101 |
| A late cutaneous response in actively sensitized rats: a new method for evaluating the efficacy of antiallergic drugs. | Journal of pharmacological sciences 20060801 |
| Prophylactic effect of pemirolast, an antiallergic agent, against hypersensitivity reactions to paclitaxel in patients with ovarian cancer. | International journal of cancer 20060515 |
| Tetrazole compounds: the effect of structure and pH on Caco-2 cell permeability. | Journal of pharmaceutical sciences 20060401 |
| Peripheral interstitial keratitis: a novel manifestation of ocular mastocytosis. | Cornea 20060401 |
| Comparison of antigen-induced leukotriene and histamine release from nasal scrapings in allergic rhinitis. | Rhinology 20050901 |
| Increasing effect by simultaneous use of levocabastine and pemirolast on experimental allergic conjunctivitis in rats. | Biological & pharmaceutical bulletin 20050301 |
| Pemirolast potently attenuates paclitaxel hypersensitivity reactions through inhibition of the release of sensory neuropeptides in rats. | Neuropharmacology 20040501 |
| A comparative trial of the safety and efficacy of 0.1 percent pemirolast potassium ophthalmic solution dosed twice or four times a day in patients with seasonal allergic conjunctivitis. | Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20040401 |
| Comparison of 0.1% bromfenac sodium and 0.1% pemirolast potassium for the treatment of allergic conjunctivitis. | Japanese journal of ophthalmology 20040101 |
| Preventive effect of an antiallergic drug, pemirolast potassium, on restenosis after stent placement: quantitative coronary angiography and intravascular ultrasound studies. | Journal of cardiology 20030701 |
| A combined analysis of two studies assessing the ocular comfort of antiallergy ophthalmic agents. | Clinical therapeutics 20030401 |
| Two mast cell stabilizers, pemirolast potassium 0.1% and nedocromil sodium 2%, in the treatment of seasonal allergic conjunctivitis: a comparative study. | Advances in therapy 20030101 |
| Pemirolast potassium 0.1% ophthalmic solution is an effective treatment for allergic conjunctivitis: a pooled analysis of two prospective, randomized, double-masked, placebo-controlled, phase III studies. | Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20021001 |
| Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells. | Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 19971201 |
| A pilot study of pemirolast in patients with seasonal allergic rhinitis. | Annals of allergy 19910201 |